Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 21Esophageal Squamous Cell Carcinoma 19Esophageal Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Hodgkin Disease 6Cholangiocarcinoma 6Liver Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Advanced Solid Tumor 4Advanced Gastric Cancer 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

Cisplatin 18Docetaxel 17Cetuximab 12Carboplatin 12Magnetic Resonance Spectroscopy 10pembrolizumab 9Radiotherapy 9Paclitaxel 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Biopsy 7Specimen Handling 6Radiotherapy, Intensity-Modulated 6Radiotherapy, Conformal 5Radiosurgery 5Fluorodeoxyglucose F18 5Chemotherapy, Adjuvant 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Nivolumab 4Bevacizumab 4sargramostim 3Radiation 3Platinum 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Salivary Gland Neoplasms × camrelizumab × Clear all
NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡